These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 10934306

  • 1. Dyslipidemias and the primary prevention of cardiovascular disease: analysis of the FAMUS primary care register.
    Xhignesse M, Laplante P, Niyonsenga T, Courteau J, Grant AM.
    Can J Cardiol; 2000 Jul; 16(7):879-85. PubMed ID: 10934306
    [Abstract] [Full Text] [Related]

  • 2. Antiplatelet and lipid-lowering therapies for the secondary prevention of cardiovascular disease: are we doing enough?
    Xhignesse M, Laplante P, Grant AM, Niyonsenga T, Delisle E, Vanasse N, Bernier R.
    Can J Cardiol; 1999 Feb; 15(2):185-9. PubMed ID: 10079778
    [Abstract] [Full Text] [Related]

  • 3. Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis.
    Petrella RJ, Merikle E, Jones J.
    Clin Ther; 2007 Apr; 29(4):742-50. PubMed ID: 17617298
    [Abstract] [Full Text] [Related]

  • 4. Primary prevention of cardiovascular diseases by lipid-lowering treatment in German general practice: results from GPs ignoring guidelines and risk calculators.
    Oriol-Zerbe C, Abholz HH.
    Eur J Gen Pract; 2007 Apr; 13(1):27-34. PubMed ID: 17366291
    [Abstract] [Full Text] [Related]

  • 5. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E, Laforest L, Burke T, Phatak H, Souchet T.
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Achieving vascular risk factor targets: a survey of a London general practice.
    Levine AP, Mikhailidis DP, Moross T, Benson K, Gor M.
    Angiology; 2008 Aug; 59(1):36-46. PubMed ID: 18319220
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Follow-up in a lipid clinic improves the management of risk factors in cardiovascular disease patients.
    Gavish D, Leibovitz E, Elly I, Shargorodsky M, Zimlichman R.
    Isr Med Assoc J; 2002 Sep; 4(9):694-7. PubMed ID: 12440233
    [Abstract] [Full Text] [Related]

  • 10. Sex differences in risk factor control of treated hypertensives: a national primary healthcare-based study in Sweden.
    Journath G, Hellénius ML, Petersson U, Theobald H, Nilsson PM, Hyper-Q Study Group Sweden.
    Eur J Cardiovasc Prev Rehabil; 2008 Jun; 15(3):258-62. PubMed ID: 18525379
    [Abstract] [Full Text] [Related]

  • 11. Increase in lipid-lowering treatment rates among TRICARE beneficiaries: a population-based study.
    Devine J, Linton A, Mistry H, Napier J, Trice S, Bacon T.
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):891-9. PubMed ID: 19634117
    [Abstract] [Full Text] [Related]

  • 12. Consequences of using different methods to assess cardiovascular risk in primary care.
    Fornasini M, Brotons C, Sellarès J, Martinez M, Galán ML, Sáenz I, da Pena JM.
    Fam Pract; 2006 Feb; 23(1):28-33. PubMed ID: 16243952
    [Abstract] [Full Text] [Related]

  • 13. Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus.
    Udawat H, Goyal RK.
    Indian Heart J; 2001 Feb; 53(2):172-6. PubMed ID: 11428472
    [Abstract] [Full Text] [Related]

  • 14. Cardiovascular medications in primary care: treatment gaps and targeting by absolute risk.
    Rafter N, Connor J, Hall J, Jackson R, Martin I, Parag V, Vander Hoorn S, Rodgers A.
    N Z Med J; 2005 Oct 07; 118(1223):U1676. PubMed ID: 16224500
    [Abstract] [Full Text] [Related]

  • 15. The SaM (Screening and Monitoring) approach to cardiovascular risk-reduction in primary care--cyclic monitoring and individual treatment of patients at cardiovascular risk using the electronic medical record.
    Rabinowitz I, Tamir A.
    Eur J Cardiovasc Prev Rehabil; 2005 Feb 07; 12(1):56-62. PubMed ID: 15703507
    [Abstract] [Full Text] [Related]

  • 16. [Cost of cardiovascular risk factor prevention in middle-aged French men. The PRIME study].
    Marques-Vidal P, Arveiler D, Amouyel P, Ducimetière P, Ferrières J.
    Rev Epidemiol Sante Publique; 2001 Dec 07; 49(6):541-9. PubMed ID: 11845103
    [Abstract] [Full Text] [Related]

  • 17. [Cardiovascular risk factors and prevention in women: similarities and differences].
    Sclavo M.
    Ital Heart J Suppl; 2001 Feb 07; 2(2):125-41. PubMed ID: 11255880
    [Abstract] [Full Text] [Related]

  • 18. Growth in use of lipid-lowering therapies: are we targeting the right patients?
    Dubois RW, Alexander CM, Wade S, Mosso A, Markson L, Lu JD, Nag S, Berger ML.
    Am J Manag Care; 2002 Oct 07; 8(10):862-7. PubMed ID: 12395954
    [Abstract] [Full Text] [Related]

  • 19. Coronary risk estimates and decisions on lipid-lowering treatment in primary prevention: comparison between general practitioners, internists, and cardiologists.
    Vancheri F, Strender LE, Montgomery H, Skånér Y, Backlund LG.
    Eur J Intern Med; 2009 Oct 07; 20(6):601-6. PubMed ID: 19782921
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of lipid-lowering treatment according to lipid level.
    Pilote L, Ho V, Lavoie F, Coupal L, Zowall H, Grover SA.
    Can J Cardiol; 2005 Jun 07; 21(8):681-7. PubMed ID: 16003451
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.